



NIH SCIENTIFIC MANAGEMENT REVIEW
BOARD



**Translational Medicine and Therapeutics
Working Group**

ROSTER

Non-Federal Members

Arthur H. Rubenstein, M.B.B.Ch.
(Chair)

Executive Vice President, University of
Pennsylvania for the Health System and
Dean, University of Pennsylvania
School of Medicine, Philadelphia, PA

William R. Brody, M.D., Ph.D.
President, Salk Institute for Biological
Studies, La Jolla, CA

Gail H. Cassell, Ph.D.
Vice President, Scientific Affairs, Eli
Lilly and Company, Indianapolis, IN

William L. Roper, M.D., M.P.H.
Dean of the School of Medicine, Vice
Chancellor for Medical Affairs,
and CEO of the UNC Health Care
System, University of North Carolina
Chapel Hill, NC

Solomon H. Snyder, M.D.
Professor of Neuroscience, Pharmacology
and Molecular Sciences, and Psychiatry,
Johns Hopkins University
Baltimore, MD

Huda Y. Zoghbi, M.D.
Professor and Howard Hughes Medical
Institute Investigator, Baylor College of
Medicine, Houston, TX

Norman Augustine *ad hoc*
Retired Chairman and CEO,
Lockheed Martin Corporation
Bethesda, MD

Federal Members

Josephine P. Briggs, M.D.
Director, National Center for
Complementary and Alternative
Medicine, NIH, Bethesda, MD

Anthony Fauci, M.D.
Director, National Institute of Allergy
and Infectious Diseases, NIH,
Bethesda, MD

Stephen Katz, M.D., Ph.D.
Director, National Institute of Arthritis
and Musculoskeletal and Skin Diseases,
NIH, Bethesda, MD

Griffin P. Rodgers, M.D., M.A.C.P.
Director, National Institute of Diabetes
and Digestive and Kidney Diseases, NIH,
Bethesda, MD

Susan Shurin, M.D.
Acting Director, National Heart, Lung,
and Blood Institute, NIH, Bethesda, MD

Harold Varmus, M.D.
Director, National Cancer Institute, NIH,
Bethesda, MD

Francis S. Collins, M.D., Ph.D.
nonvoting, ex officio
Director, NIH
Bethesda, MD